Aubry A F, Markoglou N, Adams M H, Longstreth J, Wainer I W
Department of Oncology, McGill University, Montreal, Quebec, Canada.
J Pharm Pharmacol. 1995 Nov;47(11):937-44. doi: 10.1111/j.2042-7158.1995.tb03274.x.
The binding of the non-steroidal anti-inflammatory drug oxaprozin to human serum albumin was studied by bioaffinity high-performance liquid chromatography using a column based on immobilized human serum albumin. Displacement studies using marker compounds for the major drug binding sites showed that oxaprozin has a high affinity for the benzodiazepine/indole site and binds to the warfarin site but with a significantly lower affinity. Biochromatography and ultrafiltration techniques were used to screen for possible competition and allosteric interactions between oxaprozin and potential co-administered drugs including non-steroidal anti-inflammatory drugs, antipyretics, hypoglycaemics, inhibitors of angiotensin-converting enzyme, anaesthetics, metal ions and anticancer agents. Competition occurred mainly with drugs bound at the benzodiazepine site (benzodiazepines, various non-steroidal anti-inflammatories).
采用基于固定化人血清白蛋白的柱,通过生物亲和高效液相色谱法研究了非甾体抗炎药恶丙嗪与人血清白蛋白的结合。使用主要药物结合位点的标记化合物进行的置换研究表明,恶丙嗪对苯二氮䓬/吲哚位点具有高亲和力,并与华法林位点结合,但亲和力显著较低。采用生物色谱法和超滤技术筛选恶丙嗪与潜在合用药物(包括非甾体抗炎药、解热药、降血糖药、血管紧张素转换酶抑制剂、麻醉剂、金属离子和抗癌药)之间可能的竞争和变构相互作用。竞争主要发生在与苯二氮䓬位点结合的药物(苯二氮䓬类、各种非甾体抗炎药)之间。